血清AFP、CA19-9、CEA联合检验对原发性肝癌的早期诊断价值研究
Study on the early diagnostic value of serum AFP, CA19-9, CEA combined test for primary liver cancer
ES评分 0
| DOI |
10.12208/j.ijcr.20250169 |
| 刊名 |
International Journal of Clinical Research
|
| 年，卷(期) |
2025, 9(3) |
| 作者 |
|
| 作者单位 |
甘肃陇西县第二人民医院 甘肃定西
|
| 摘要 |
目的 分析血清AFP、CA19-9、CEA联合检验对原发性肝癌的早期诊断价值。方法 选择2023年1-12月于我院确诊的慢性肝炎、肝硬化、原发性肝癌，健康体检者各80例，行血清AFP、CA19-9、CEA检验，对比不同患者标志物检出率、对比血清AFP、CA19-9、CEA联合检验的诊断效能。结果 原发性肝癌血清AFP、CA19-9、CEA联合检出率最高，血清AFP、CA19-9、CEA联合检验的诊断效能高于单一检测，差异有统计学意义（P﹤0.05），结论 血清AFP、CA19-9、CEA联合检验可筛查出原发性肝癌，利于确诊疾病和指导后续治疗。
|
| Abstract |
Objective To analyze the early diagnostic value of serum AFP, CA19-9, CEA combined test for primary liver cancer. Methods Eighty healthy individuals diagnosed with chronic hepatitis, cirrhosis, and primary liver cancer in our hospital from January to December 2023 were selected for serum AFP, CA19-9, and CEA tests. The detection rates of different patient biomarkers and the diagnostic efficacy of combined serum AFP, CA19-9, and CEA tests were compared. Results The combined detection rate of serum AFP, CA19-9, and CEA was the highest in primary liver cancer. The diagnostic efficacy of the combined test of serum AFP, CA19-9, and CEA was higher than that of a single test, and the difference was statistically significant (P<0.05). Conclusion The combined test of serum AFP, CA19-9, and CEA can screen for primary liver cancer, which is beneficial for diagnosing the disease and guiding subsequent treatment.
|
| 关键词 |
血清AFP；CA19-9；CEA；联合检验；原发性肝癌的早期诊断；癌胚抗原；糖蛋白
|
| KeyWord |
Serum AFP; CA19-9; CEA; Joint inspection; Early diagnosis of primary liver cancer; Carcinoembryonic antigen; Glycoprotein
|
| 基金项目 |
|
| 页码 |
194-196 |
罗变红*.
血清AFP、CA19-9、CEA联合检验对原发性肝癌的早期诊断价值研究 [J].
国际临床研究杂志.
2025; 9; (3).
194 - 196.